- STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
- Alvotech Announces Closing of Private Debt Financing
- Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma
- Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
- Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
- Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
- Alvotech Issues New Shares to Holders of Convertible Bonds
- Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
- Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024
More ▼
Key statistics
On Monday, Alvotech SA (ALVO:NMQ) closed at 12.00, 44.75% above the 52 week low of 8.29 set on Sep 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.04 |
---|---|
High | 12.05 |
Low | 11.80 |
Bid | 11.50 |
Offer | 13.01 |
Previous close | 12.00 |
Average volume | 49.58k |
---|---|
Shares outstanding | 301.94m |
Free float | 107.75m |
P/E (TTM) | -- |
Market cap | 3.62bn USD |
EPS (TTM) | -2.05 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼